DNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer by Wang, Gary P. et al.
Published online 14 April 2008 Nucleic Acids Research, 2008, Vol. 36, No. 9 e49
doi:10.1093/nar/gkn125
DNA bar coding and pyrosequencing to analyze
adverse events in therapeutic gene transfer
Gary P. Wang
1, Alexandrine Garrigue
2, Angela Ciuffi
1, Keshet Ronen
1, Jeremy Leipzig
1,
Charles Berry
3, Chantal Lagresle-Peyrou
2,4, Fatine Benjelloun
2,4,
Salima Hacein-Bey-Abina
2,5, Alain Fischer
2,4,6, Marina Cavazzana-Calvo
2,4,5
and Frederic D. Bushman
1,*
1University of Pennsylvania School of Medicine, Department of Microbiology, 3610 Hamilton Walk, Philadelphia,
PA 19104-6076, USA,
2INSERM Unit 768Ho ˆpital Necker Enfants Malades 149 rue de Se `vres, 75015 Paris, France,
3Department of Family/Preventive Medicine, University of California, San Diego School of Medicine, San Diego, CA
92093, USA,
4Faculte ´ de Me ´decine Rene ´ Descartes, Universite ´ Paris-Descartes,
5Assistance Publique,
De ´partement de Biotherapie and
6Assistance Publique, Ho ˆpitaux de Paris (AP/HP), Service d’Immunologie et
d’He ´matologie Pe ´diatriques, Ho ˆpital Necker Enfants Malades, Ho ˆpital Necker Enfants Malades 149 rue de Se `vres,
75015 Paris, France
Received January 2, 2008; Revised March 4, 2008; Accepted March 5, 2008
ABSTRACT
Gene transfer has been used to correct inherited
immunodeficiencies, but in several patients integra-
tion of therapeutic retroviral vectors activated
proto-oncogenes and caused leukemia. Here, we
describe improved methods for characterizing inte-
gration site populations from gene transfer studies
using DNA bar coding and pyrosequencing. We
characterized 160 232 integration site sequences in
28 tissue samples from eight mice, where Rag1 or
Artemis deficiencies were corrected by introducing
the missing gene with gamma-retroviral or lentiviral
vectors. The integration sites were characterized for
their genomic distributions, including proximity to
proto-oncogenes. Several mice harbored abnormal
lymphoproliferations following therapy—in these
cases, comparison of the location and frequency
of isolation of integration sites across multiple
tissues helped clarify the contribution of specific
proviruses to the adverse events. We also took
advantage of the large number of pyrosequencing
reads to show that recovery of integration sites can
be highly biased by the use of restriction enzyme
cleavage of genomic DNA, which is a limitation in all
widely used methods, but describe improved
approaches that take advantage of the power
of pyrosequencing to overcome this problem.
The methods described here should allow integra-
tion site populations from human gene therapy to be
deeply characterized with spatial and temporal
resolution.
INTRODUCTION
Successful correction of human genetic diseases has been
achieved for X-linked severe combined immunodeﬁciency
(SCID) (1), adenosine deaminase deﬁciency (ADA-SCID)
(2) and chronic granulomatous disease (CGD) (3).
However, several serious adverse events occurred during
therapeutic gene transfer for X-SCID, in which the
gamma-retrovirus-based vectors used for gene correction
integrated near cellular proto-oncogenes and contributed
to transformation (4,5). For this reason there is intense
interest in improving methods for analyzing integration
site placement during gene therapy, both to allow
monitoring of possible incipient adverse events and to
guide the development of safer integrating vectors. Here,
we describe the use of DNA bar coding and pyrosequenc-
ing to allow eﬃcient determination of integration site
sequences from many samples, using murine models of
therapeutic gene transfer.
Human severe combined immunodeﬁciencies have been
identiﬁed that involve mutations in the genes for the
Artemis and Rag1 proteins, prompting interest in devising
gene correction strategies (6–8). For the Artemis gene, two
groups have devised lentiviral vectors capable of gene
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ducing Rag1 is available (11). However, questions of
genotoxicity have arisen in both models, which we have
investigated in this study.
For the Artemis model, the mice are tumor prone due
to the loss of Artemis itself, particularly in combination
with conditioning prior to cell transfer with irradiation, as
was used in pilot studies (12). Thus elevated transforma-
tion rates were expected after gene transduction, and it
was observed that some of the transformed cells harbored
integrated lentiviral vectors. Similarly, lymphoprolifera-
tions were seen in Rag1 gene corrected mice, and analysis
of transformed cells showed that they contained integrated
gamma-retroviral vectors (11). It was thus of interest to
investigate whether transformation might involve inser-
tional activation of proto-oncogenes.
Here, we describe the use of DNA bar coding and
pyrosequencing to monitor genotoxicity during gene
correction. We used the massively parallel pyrosequencing
method commercialized by 454 Life Sciences (13), which
at the time this work was carried out was capable of
generating up to 200000 sequence reads of about 100bp
each per run (since then, the numbers of reads available
per run and the read lengths have increased). The DNA
bar coding method (14–16) allowed amplicons from
diﬀerent samples to be pooled for sequencing, then
separated afterwards using information contained in the
DNA bar codes. In the study reported here, we demon-
strate the utility of these methods by analyzing the spatial
distribution of integration sites in gene-corrected mice
with lymphoproliferations or healthy controls. We ana-
lyzed 28 tissue samples from eight mice, each sample with
a unique DNA bar code. After quality control, 160232
sequence reads could be mapped to unique sites on the
murine genome. Because of the very large number of
sequence reads available, integration sites could be
annotated with their frequency of recovery, providing
information relevant to evaluating possible insertional
activation of proto-oncogenes and the distribution of
transduced cell clones. We also show that the typical
recovery methods used for integration sites isolation are
highly biased, but the use of pyrosequencing has the
potential to overpower the problem. Together these data
illustrate a collection of methods that substantially
improves our ability to monitor populations of integration
sites generated during therapeutic gene transfer.
MATERIALS AND METHODS
Vector transduction and preparation of tissuesamples
The construction and preparation of lentiviral and
gamma-retroviral vectors, and transduction of hemato-
poietic stem cells are described in (10,11). To identify
integration site sequences, mice were sacriﬁced and
genomic DNA was isolated from tissues indicated in
Table 1, as described (10,11).
As controls, murine embryonic ﬁbroblasts (MEFs) were
transduced with either a lentiviral vector or a gamma-
retroviral vector, followed by integration site analysis.
MEFs were cultured in DMEM supplemented with
10% heat-inactivated FCS, 2mM glutamine, 0.1mM
b-mercaptoethanol, nonessential amino acids, 1mM
sodium pyruvate and 50mg/ml gentamycin. The lentiviral
vector was prepared as described previously (17,18). The
gamma-retroviral vector was prepared by transfection of
the MLV vector segment (pMLV LTR-GFP), the packag-
ing construct pCGP producing the MLV Gag and
Pol polyproteins (pCGP), and the vesicular stomatitis
virus G-producing plasmid (pMD.G). Viral supernatant
was harvested 48h after transfection, ﬁltered through
0.45mm ﬁlters, concentrated, treated with DNaseI, and
stored frozen at  808C. To isolate integration sites, MEFs
(3 10
6 in a 10cm dish) were inoculated with 1mg of p24
capsid antigen for 7–15h in the presence of 10mg/ml
DEAE-dextran, washed, and cultured for additional 48h
in culture medium. Cells were harvested, genomic DNA
was isolated and isolation of the integration sites was
performed as described subsequently.
Isolation of integration site sequences
To determine vector integration sites on the mouse
genome, DNA fragments from host–vector junction were
prepared using ligation-mediated PCR (6,17–20). Brieﬂy,
each DNA sample (1–1.5mg) was digested with MseI. The
digested samples were ligated to linkers, and then ampliﬁed
by nested PCR. In order to sequence all the samples in a
single sequencing experiment, primers that contain unique
4-bp barcodes were used in the second PCR step (Figure 1,
Supplementary Table 1). The PCR products were gel
puriﬁed, pooled, and then subjected to pyrosequencing as
implemented by 454 Life Sciences (13). To minimize bar
code ‘crossover’, the mouse samples were separated into
four quadrants on a single picotiter sequencing plate.
Inspection of the integration sites revealed 23 instances
(<0.01% of total sequence reads) in which an identical
integration site was observed in diﬀerent mice in the same
quadrant with barcodes of edit distance 1 (i.e. ‘barcode
collisions’). These barcode collisions were resolved by
removing all collision sites from the sample with the lower
number of clones (which was usually one).
Integration sites were judged to be authentic if the
sequences began within 3bp of vector LTR ends, had
either a >98% sequence match or no more than one base
mismatch if the read length was <50bp, and had a unique
best hit when aligned to the draft mouse genome (mm8)
using BLAT. The sequence data from this study have been
submitted to GenBank under accession nos. ET648700-
ET656552.
The lymphoproliferation samples from mouse 8, 31 and
613 were additionally analyzed by LAM-PCR (21).
Brieﬂy, 50 Biotinylated primers LTRI (50-GAGCTCTCT
GGCTAACTAGG-30) and LTRII (50-GAACCCACTGC
TTAAGCCTCA-30) were used for pre-ampliﬁcation of the
vector-host junctions. After magnetic capture, hexanu-
cleotide priming, and restriction digestion with Tsp509I, a
linker cassette was ligated to the 30 end of the genomic
sequence. First exponential ampliﬁcation of the vector-
host junction was performed using linker cassette primer
LCI and vector LTR speciﬁc primer LTRIII (50-AGC
TTGCCTTGAGTGCTTCA-30), followed by second
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TAGTGTGTGCCCGTCTGT-30). The ﬁnal PCR pro-
duct was separated on a spreadex high- resolution gel
(Elchrom, Cham, Switzerland). Isolated speciﬁc DNA
bands or LAM-PCR amplicons were puriﬁed, shotgun
cloned into TOPO TA vector (Invitrogen, Carlsbad, CA,
USA) and sequenced (GATC, Konstanz, Germany) using
the Sanger method. Integration site sequences were
aligned to the mouse genome as described before.
Cancer genedatabase (‘Cancergenes’)
To determine integration frequency near proto-oncogenes
and tumor suppressors from tissue samples, a ‘Cancer-
gene’ database was compiled from seven sources: (i) http://
atlasgeneticsoncology.org (22); (ii) http://rtcgd.abcc.ncif
crf.gov (23); (iii) http://www.sanger.ac.uk/genetics/CGP/
Census/(24); (iv) http://cc.ucsf.edu/people/waldman/GEN
ES/completechroms.html; (v) Sjoblom et al. (25);
Table 1. Tissues analyzed by integration site sequencing and frequency of integration near Cancergenes
Mouse Disease state Tissue Integration sites Sites within
50kb cancergenes
50 end
Percentage of
Cancergenes
(tissue)
Percentage of
Cancergenes
(mouse)
Total reads
(unique sites)
Total reads
(unique sites)
Total reads
(unique sites)
Total reads
(unique sites)
Gamma-retroviral vector in rag-deﬁcient mice
1 Healthy control LN 2360 (274) 269 (45) 11.4 (16.4) 10.1 (15.3)
marrow 2701 (101) 137 (17) 5.1 (16.8)
thymus 3262 (103) 436 (11) 13.4 (10.7)
215 Lymphoproliferation LN 6950 (60) 262 (6) 3.8 (10.0) 3.3 (13.6)
marrow 1893 (33) 39 (3) 2.1 (9.1)
spleen 4734 (48) 173 (7) 3.7 (14.6)
thymus 4044 (43) 104 (9) 2.6 (20.9)
X Lymphoproliferation liver 4049 (40) 1344 (10) 33.2 (25.0) 33.3 (23.5)
marrow 4160 (53) 1433 (11) 34.4 (20.8)
spleen 5287 (43) 1717 (11) 32.5 (25.6)
Lentiviral (EF1a) vector in artemis-deﬁcient mice
22 Healthy control LN 7789 (325) 268 (21) 3.4 (6.5) 5.1 (6.0)
marrow 3387 (89) 322 (4) 9.5 (4.5)
spleen 7028 (252) 482 (16) 6.9 (6.3)
thymus 3325 (50) 25 (2) 0.8 (4.0)
31 Healthy cells pretransplantation Sca1+ 9574 (337) 735 (25) 7.7 (7.4) 7.7 (7.4)
Lymphoproliferation LN 3687 (215) 89 (20) 2.4 (9.3) 1.7 (9.0)
spleen 1669 (6) 0 (0) 0 (0)
8 Healthy cells pretransplantation Sca1+ 10648 (265) 597 (18) 5.6 (6.8) 5.6 (6.8)
Lymphoproliferation LN 737 (46) 3 (3) 0.4 (6.5) 0.04 (3.9)
liver 14041 (11) 0 (0) 0 (0)
pleural ﬂuid 7183 (55) 13 (3) 0.2 (5.5)
spleen 7179 (18) 0 (0) 0 (0)
thymus 12290 (23) 0 (0) 0 (0)
Lentiviral (PGK) vector in artemis-deﬁcient mice
401 Healthy control LN 1647 (65) 117 (4) 7.1 (6.2) 4.3 (9.5)
marrow 379 (41) 41 (4) 10.8 (9.8)
spleen 1265 (40) 40 (4) 3.2 (10.0)
thymus 2487 (53) 50 (7) 2.0 (13.2)
613 Healthy cells pretransplantation Sca1+ 26477 (37) 0 (0) 0 (0) 0 (0)
Lymphoproliferation
a LN 42 (5) 0 (0) 0 (0) 1.0 (5.9)
marrow 31 (6) 1 (1) 3.2 (16.7)
thymus 26 (6) 0 (0) 0 (0)
MLV-based vector in MEF 7420 (4828) 1003 (632) 13.5 (13.1)
HIV-based vector in MEF 3929 (2441) 329 (209) 8.4 (8.6)
aThese samples were sequenced using the Sanger method only.
LN, lymph nodes.
LTR Primer
Linker Primer host DNA vector DNA
Barcode
GCCTTGCCAGCCCGCTCAG  -    CACG CACG  -  AGACCCTTTTAGTCAGTGTGGAAAATC
454 Sequencing Primer Barcode LTR Primer
Sample primer sequence
454 Sequencing
       Primer
Linker U3 U5
Figure 1. The DNA bar coding strategy. Each LTR primer used in
ligation-mediated PCR contained a unique DNA barcode that speciﬁed
the mouse and tissue of origin. Each barcode consists of a unique 4-bp
nucleotide sequence, inserted between the sequencing primer binding
site and the LTR speciﬁc primer segment. Thus all sequencing reads
begin with the 4-bp barcode identiﬁers. A sample primer with a bar
code is shown at the bottom of the diagram.
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and (vii) a custom list of proto-oncogenes and tumor
suppressors compiled from literature sources. A composite
of these seven lists, totaling 1650 genes, was used to
annotate the integration sites. This ‘Cancergenes’ list
(allOnco) can be found at http://microb230.med.upenn.edu/
protocols/cancergenes.html.
Bioinformatic and statistical analysis
Detailed bioinformatic methods can be found in (26) and
(18), and Supplementary Data 1–4. All analysis was
carried out using the mm8 genome draft.
RESULTS
The murinemodels studied
In each model studied, Sca1+ bone marrow cells were
harvested and transduced ex vivo. Recipient mice were
irradiated to depopulate bone marrow precursors and
stem cells, and to increase the selective advantage of the
injected transduced cells. Two vectors were used for gene
correction of an Artemis knockout strain. Both were
lentiviral vectors derived from the TRIPU3-vector (27).
In one, the EF1a promoter drove expression of the
Artemis gene; in the second, the PGK promoter drove
expression (10). In the Rag1 correction model, the Rag1
gene was delivered using a gamma-retroviral vector
Lagresle-Peyrou et al. (11). In both disease models,
abnormal lymphoproliferative events were detected in
some of the mice (Table 1; detailed pathology data is
presented in Supplementary Tables 2 and 3).
Six months following Rag1 gene transfer, one mouse
(mouse X) was euthanized because of a sudden onset of
slow-moving behavior. Hepatosplenomegaly was found
due to the presence of monomorphic undiﬀerentiated
lymphocytes containing a high transgene copy number
(20 copies/cell). Studies to analyze the T-cell receptor
diversity (‘Immunoscope’ method) demonstrated that the
acute leukemic proliferation was due to the expansion of
cells containing a unique T-cell receptor gene rearrange-
ment (Vb6Va6). In an eﬀort to detect additional adverse
events, 12 mice were subjected to secondary transplanta-
tion from primary gene-corrected mice, and one of these
(mouse 215) developed an enlarged spleen inﬁltrated with
polymorphic and polyclonal B lymphocytes (10 transgene
copies/cell) at 6 months following secondary transplanta-
tion. Secondary transplantation is known to be associated
with elevated rates of abnormal lymphoproliferation (28),
leaving the possible involvement of insertional activation
during gene correction uncertain.
For the Artemis study, 9 months following Artemis gene
transfer, one mouse (mouse 8) died, and hepatosplenome-
galy was observed. Immunohistochemical studies revealed
that spleen, liver, lung and thymus were inﬁltrated with
small cells (Supplementary Table 3). A second mouse
(mouse 31) also developed lymphoproliferation 4 months
after gene transfer. Tissues were harvested from these
mice and integration site distributions analyzed. Control
mice without lymphoproliferations were also included
for comparison.
Several sets of control integration sites were analyzed
for comparison. For several of the mice, samples of the
initially transduced cell population prior to engraftment
were available and could be analyzed (labeled ‘Sca1+’ in
Table 1). As additional controls, two large data sets were
generated by ex vivo transduction of MEFs with either
a lentiviral vector or a gamma-retroviral vector, followed
by harvesting of integration sites 55–63h after transduc-
tion (Table 1). These data sets are from a diﬀerent cell type
but provide large numbers of integration sites in the
murine genome for comparison.
DNA barcoding and pyrosequencing
To prepare samples for pyrosequencing, DNA fragments
from host–virus junctions were ampliﬁed using ligation-
mediated PCR (3,17–20,29–34). Each DNA sample was
ﬁrst cleaved with MseI, which recognizes a four-base site.
The digested cellular DNA was ligated to DNA linkers,
and the junctions between the viral and cellular DNA were
ampliﬁed using nested PCR.
In order to allow multiplex sequencing of many DNA
samples in a single experiment, we took advantage of
DNA bar coding (14–16). For the second PCR step, we
used primers that contain unique 4-bp barcodes to identify
each sequence (Figure 1). The PCR amplicons from each
sample were gel puriﬁed and pooled together, then
subjected to pyrosequencing using the method commer-
cialized by 454 Life Sciences (13). We obtained a total of
274 575 raw sequence reads, averaging  100bp in length.
Each sequence was then assigned to a sample according
to its barcode. Sequences from all samples were recovered
in good yield (Table 1). After quality control, 160 232 total
integration site sequence reads were available for analysis,
which correspond to 2726 unique integration sites on the
murine genome. The redundancy in sequence reads per
integration site likely arose both from cell division in vivo
and PCR ampliﬁcation during DNA isolation. Integration
sites generated by acute infection of MEFs were isolated in
a similar fashion and yielded a total of 11 349 reads, which
correspond to 7269 unique integration sites.
For mouse 8 and 31, an additional 104 sites were cloned
from the tissues with lymphoproliferation by cleaving
genomic DNA with the enzyme Tsp509I, linker ligation,
PCR ampliﬁcation and cloning in bacteria, followed by
sequencing using the Sanger method. Subsequently, we
compare the distributions of these sites with those
analyzed using MseI cleavage and pyrosequencing.
Overviewofthedistributionofvectorintegrationsitesinmice
An analysis of integration site distributions in mice and
cell culture controls are shown in Figure 2. More detailed
catalogs of integration site distributions are presented in
Supplementary Data 1–3. To maximize the sensitivity of
statistical tests, the integration site data were pooled in
several ways, and integration frequency assessed near
recognizable genomic features. In one approach, the
integration site data was pooled to allow comparison of
lymphoproliferation samples versus healthy tissue, and
subdivided by lentiviral vector and gamma-retroviral
vector (Supplementary Data 1). As in previous studies
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vectors was strongly favored within transcription units
(Figure 2A). The gamma-retroviral vectors showed a
weaker though still signiﬁcant preference, also paralleling
previous work (19,20,22,23,35–37). Integration site popu-
lations recovered from mice were not greatly diﬀerent
from sites in MEFs, indicating that evolution of trans-
duced cells in vivo did not strongly aﬀect the site distri-
butions relative to transcription units.
The gamma-retrovirus-based vectors showed preferen-
tial integration near transcription start sites compared to
random controls (Figure 2B). CpG islands are probable
regulatory regions associated with gene 50 ends, and the
gamma-retroviral vectors showed particularly strongly
favored integration near these features (Figure 2C), as
anticipated from previous studies (19,20). Integration
by the lentiviral vectors was disfavored within 1kb of
CpG islands.
Integration near transcription units was examined for
each mouse individually, and integration was found to be
favored near transcription units in each (Figure 2D and
Supplementary Data 2). For some of the samples the
numbers of available sites were modest, diminishing
the resolution of the data. In general, the samples from
animals transduced with the lentiviral vector showed
more frequent integration within transcription units than
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Figure 2. Lentiviral vector and gamma-retroviral vector integration site distributions in the murine genome. Vector integration sites for pooled
samples were compared to their matched random control sites. In the matching procedure (20), each unique integration site was matched with 10
control sites in the genome randomly selected in silico that were constrained to lie the same distance from an MseI recognition site as the
experimentally determined integration site. Comparison of experimentally determined integration sites to the matched random controls thus ‘washed
out’ any possible biases introduced by the use of MseI cleavage. A value above 1 indicates favored integration relative to random control sites; a
value below 1 indicates disfavored integration. (A) Frequency of integration in transcription units. MEF: control integration sites from cultured
murine embryonic ﬁbroblasts. Healthy: control healthy mice. Tumor: mice with lymphoproliferation. (B) Frequency of integration near transcription
start site. (C) Frequency of integration near CpG islands. (D) Frequency of integration in transcription units. In this analysis the integration site data
sets are pooled for all tissues from each mouse. (E) Frequency of integration in transcription units for integration sites pooled by tissue of origin
(samples from liver are not included in this analysis due to the low number of integration sites). Comparisons between the lentiviral and gamma-
retroviral vectors in each of the panels achieved P <0.0001 (Fisher’s exact test). Comprehensive analysis of integration frequency relative to many
genomic features can be found in Supplementary Data 1–3.
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outlier (we return to the distinctive features in mouse X
subsequently).
We also investigated whether there were systematic diﬀ-
erences in integration site distributions by the organ of
origin of the tissue sample. Comparison over a variety of
genomic features showed no notable trends associated with
speciﬁc organs (Figure 2E and Supplementary Data 3).
Analysisof integration frequency near
proto-oncogenes and tumorsuppressors
To identify integration sites near proto-oncogenes
and tumor supressors that might contribute to insertional
activation, we assembled a database of reported
proto-oncogenes and tumor suppressors (summarized in
http://microb230.med.upenn.edu/protocols/cancergenes.html)
and used them to annotate the integration sites isolated
from the murine samples. To assemble as comprehensive a
database as possible, proto-oncogenes and tumor suppres-
sors identiﬁed in diverse vertebrates were analyzed to
identify their murine orthologs, and these genes added
to the database (termed ‘Cancergenes’ subsequently). The
Cancergeneslistwasthenusedinqueriesagainstintegration
sites. The large number of pyrosequencing reads allowed
us to quantify the percent of integration sites within 50kb
of a Cancergene 50 end as a fraction of total number of
sites (Table 1). Separate percentages are shown for each
mouse and tissue combination analyzed individually, and
forpooledintegrationsiteswithineachmouse.Ineachcase,
thefrequenciesofintegrationnearCancergeneswereevalu-
ated both based on the number of raw sequences reads,
and unique integration sites generated after de-replicating
duplicatereads.
Starting with the gamma-retroviral vector samples, we
could compare one control mouse (mouse 1) to two mice
harboring lymphoproliferative events (mice 215 and X).
As an estimate of the initial frequency of integration near
Cancergenes, we also analyzed data from MEF cells
transduced in culture with the gamma-retroviral vector.
Control mouse 1 showed 10.1% of total integration site
sequence reads (15.3% of unique integration sites) within
50kb of a Cancergene 50 end, and for the MEF control,
13.5% of total integration site sequence reads (13.1%
unique integration sites) were within 50kb of a Cancer-
gene 50 end. Similar frequencies of integration near Can-
cergene 50 ends are seen for gamma-retroviral vectors in
human cells (38), suggesting that the frequency may not be
strongly cell-type speciﬁc.
Pooled sites from mouse X showed a signiﬁcantly higher
proportion of integration near Cancergene 50 ends
compared to the MEF control (P<0.0001; chi-square)
based on total integration site sequence reads. Such a
trend was not seen for both mouse 1 and mouse 215, and
in fact the proportion of sites near Cancergenes were lower
compared to the MEF control (P<0.0001; chi-square).
In addition, the proportion of sites near Cancergenes in
mouse X was higher than the proportion in control mouse
1( P<0.0001; chi-square) and also mouse 215 (P<0.0001;
chi-square). This suggests that cells harboring integra-
tion sites near Cancergenes in mouse X became more
abundant during growth in vivo. Analysis of the lympho-
proliferations in these mice revealed that the expanded cell
population in mouse X was of monoclonal origin,
consistent with insertional activation [(11) and Supple-
mentary Table 2]. In contrast, the lymphoproliferative
event in mouse 215 was polyclonal and integration near
Cancergene 50 ends was not signiﬁcantly enriched.
For the study using lentiviral vectors to correct the
Artemis defect, the combination of the Artemis knockout
and conditioning by irradiation is known to result in a
high level of transformation. Thus, although transformed
cells did harbor integrated lentiviral vectors, it was
uncertain whether the observed lymphoproliferative
events were a result of insertional activation or back-
ground transformation in the model. Five gene-corrected
mice were studied, two controls (mice 22 and 401) and
three with abnormal lymphoproliferation (mice 31, 8 and
613; Table 1). For all three lentiviral vector-corrected mice
with abnormal lymphoproliferations, control samples of
transduced Sca1+ cells from before transplantation were
also available for comparison. Because the numbers of
integration sites were low for some of the mouse and
organ combinations, integration site reads from all organs
were pooled for initial analysis. The proportions of
integration near Cancergene 50 ends for the mice ranged
from 0% to 7.7% based on total sequence reads (0% to
9.5% based on unique integration sites). In the lentiviral
vector-transduced MEF control, 8.4% of total integration
site sequence reads (8.6% of unique integration sites) were
near the 50 ends of Cancergenes. None of the values for
lentivirus-transduced lymphoproliferation samples was
signiﬁcantly greater than the value from the lentiviral
integration in the MEF control (in fact, all the values
based on total sequence reads were lower). Thus these
data show no enrichment of integration near Cancergenes
in the lymphoproliferation samples and so fail to
strengthen the idea that insertional activation by the
lentiviral vector contributed to transformation.
Insertional activationand cell proliferation assessed
using integration site sequence counts
The large numbers of pyrosequencing reads allowed us to
carry out another form of analysis, taking advantage of
not just the locations of sequenced integration sites, but
also the number of times each sequence was recovered.
In this analysis, we assumed that the frequency of
integration sites in the initial pool of cells is related to
the number of sequence reads recovered, though as is
discussed subsequently there are probable distortions due
to diﬀerential isolation.
One useful analysis involved the comparison of the
location and numbers of integration sites among tissues
within individual mice. Inﬁltration of tissues by trans-
formed cells is expected to be associated with advanced
disease. Thus the identiﬁcation of identical integration
sites near Cancergenes that are abundant in multiple
diﬀerent tissues indicates probable insertional activation
and spread after transformation. For mouse X, which
harbored the apparent insertional activation event, a small
number of integration sites were extremely abundant,
e49 Nucleic Acids Research, 2008, Vol. 36, No. 9 PAGE6 OF12and clones that were highly abundant in any one of the
three tissues analyzed were also abundant in the other two
(Figure 3; a detailed analysis of all mice studied is
presented in Supplementary Data 4). This tendency is
reﬂected in the higher Spearman correlations of clone
counts in pairs of tissues and in scatterplots of those
counts (Figure 3A). Analysis of the most abundant
integration site sequences in mouse X showed that two
of the four most frequently recovered sites were near the
proto-oncogenes c-Fos and Pik3r2. Both integration sites
are about 29000bp upstream of the respective proto-
oncogene transcription start sites, consistent with the
idea that integration activated transcription, leading to
dissemination of the transformed cells.
Mouse 215 (Figure 3B) is an intermediate case. The
Spearman correlations for clone counts between tissues
are lower than for mouse X, and only the fourth most
abundant integration site is near a proto-oncogene
(Erbb3). The data are consistent with development of
early stage insertional activation following the secondary
bone marrow transplantation, but from these data alone
there is no strong support for transformation by inser-
tional activation.
As controls, results are shown for two healthy mice in
Figure 3C and 3D. In these cases the Spearman
correlations are lower, and the most abundant proto-
oncogene insertion is only the ninth most abundant
(Sept9 in mouse 1). Thus frequency information from
Figure 3. Correlations of clone counts between tissues in mice with abnormal lymphoproliferation (A and B) or healthy controls (C and D). The
mouse studied is indicated on the ﬁgure, along with the genes nearest the integration site. Each point represents an individual integration site; the
values on the x- and y-axes indicate the number of sequences for each clone. The square root of clone counts for each tissue is plotted to allow very
high counts to be displayed conveniently. Integration sites at known proto-oncogenes are indicated by the larger red lettering. The r-values indicate
the Spearman correlations for counts between tissues. For detailed analysis of all mice see Supplementary Data 4. We note that it is probable that
not all potential cancer-related genes have been identiﬁed. Also, for any given insertion, additional studies are required to establish whether the
integration event up-regulates Cancergene transcription.
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example of probable insertional activation and spread to
multiple tissues from polyclonal repopulation.
Differential recovery ofintegration sitesassociated with
therestriction enzymes usedto cleave genomic DNA
For some of the samples, integration site sequences were
recovered after using either of two methods: (i) cleavage
of the murine genome with Tsp509I followed by cloning
in bacteria and Sanger sequencing or (ii) cleavage by MseI
followed by pyrosequencing. The tissue samples are
expected to have many copies of each provirus due to
division of the transduced cells, allowing us to ask how
often identical sites were recovered from the same DNA
sample after recovery using the two methods.
A total of 374 unique integration sites were recovered
using MseI and 104 recovered using Tsp509I. A compar-
ison of the data sets for MseI and Tsp509I showed
that global trends in integration targeting were not
signiﬁcantly diﬀerent between the two (data not shown).
However, only 29 integration sites were common between
the two data sets (Figure 4A).
The relatively modest overlap between the two data sets
could arise for either of two reasons. It could simply be
due to sparse sampling, so that drawing two samples of a
few hundred integration sites from a much larger pool
by chance yielded little overlap. The other possibility is
that sampling was near saturation for both the MseI and
Tsp509I data sets, but that the isolation methods are so
biased that only a few integration sites are in common.
Consistent with the bias model, the average number of
sequence reads per unique site recovered was high—208 in
the MseI set and 3.5 in the Tsp509I set. However, it could
still be that a few hyper-abundant sites were recovered
many times, accounting for the high average number of
duplicates. To test this, a collector’s curve (rarefaction)
analysis was carried out, which is a technique from
quantitative ecology for comparing species richness.
Figure 3. Continued.
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into many subsets of diﬀerent sizes, and the number of
unique sites plotted (Figure 4B and C). If a plateau
number of unique sites is reached at numbers of sequence
reads well below the total sampled, then one can conclude
that further sampling will not yield many new integration
sites. As can be seen in Figure 4B and C (curves labeled
‘Sob’ for ‘Species-observed’), the curves are approaching,
though not at, a plateau value, indicating that many of
the integration sites recoverable with each method have
been isolated.
The total number of integration site sequences in the
samples could be estimated using Chao1, which uses
frequency of isolation information to estimate the unseen
number of species (integration sites) in a sample.
Collector’s curve analysis was also applied to the Chao1
estimates. As can be seen from Figure 4B and C (‘Chao1’),
the estimated values are higher than the experimental
values, indicating that the estimated total number of
integration sites is greater than the observed number. The
Chao1 estimates also approach a plateau at the highest
values. The Chao1 estimates for the total number of
recoverable integration sites in each sample was 480 for
MseI and 167 for Tsp509I.
The data in Figure 4B and C indicated that more than
half of the estimated number of integration sites was
recovered for both MseI and Tsp509I methods, yet the
shared integration sites were only 7.8% of the MseI data
set and 28% of the Tsp509I data set. We conclude that
cleavage with either of these restriction enzymes allows
recovery of only a fraction of the integration sites in the
sample, and that the recovery methods are biased by the
restriction enzymes chosen.
The origin of the recovery bias has not been fully
clariﬁed. Possible factors could include proximity to a
restriction enzyme recognition site used to cleave genomic
DNA, and possible factors aﬀecting PCR eﬃciency such
as G/C content or inverted repeat sequences within
the amplicon. To begin to investigate the origin of the
recovery bias, we asked whether proximity to MseI sites
inﬂuenced isolation frequency in the MseI data set.
Figure 5 plots frequency of isolation as a function of
this distance. The counts of identical sequence reads are
highest when the MseI site is 30–60 bases away from the
integration site. Lower frequencies were seen for integra-
tion sites that were very close or very far from the
restriction sites. Thus, proviruses integrated too near or
too far from recognition sites for the restriction enzyme
chosen will be recovered only ineﬃciently, potentially
leading to missing data. This bias due to restriction
enzymes was also seen in other integration site studies
where multiple pyrosequencing data sets were compared
(our unpublished data).
DISCUSSION
Here we present examples of the use of DNA bar coding
and pyrosequencing to monitor possible insertional
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Figure 4. Severe biases in recovery of integration sites arising due to
use of diﬀerent restriction enzymes. (A) Venn diagram indicating the
overlap between integration sites isolated by cleaving genomic DNA
with MseI versus Tsp509I. (B) Collector’s curve (rarefaction) analysis
of integration sites recovered after MseI cleavage. Repeated samples of
integration site subsets were used to evaluate whether further sampling
would likely yield additional integration sites (rarefaction analysis), as
indicated by whether the curve has reached a plateau value. The y-axis
indicates the number of integration site sequences detected, the x-axis
the number of integration sites in the subset analyzed. ‘Sob’ (Species-
observed) indicates rarefaction on the original data. The Chao1
estimator was used to estimate the number of undetected integration
sites from frequency of isolation information. ‘Chao1’ indicates
collector’s curve analysis on Chao1 estimates for sequence subsets.
(C) Collector’s curve analysis for integration sites recovered after
cleavage of genomic DNA with Tsp509I. Markings as in (B).
Figure 5. Bias in recovery of integration sites due to the distance
between integration sites and the closest MseI sites. The distribution of
counts of identical sequence reads is shown as a function of distance to
the nearest restriction site. The y-axis represents the percentage of
integration sites with the indicated frequencies of isolation, and the
x-axis is the range of distances between integration sites and their
nearby MseI restriction sites used for binning.
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transfer. As models, we tested lymphoproliferations that
arose during gene correction in mice lacking Artemis or
Rag1. To illustrate the potential of this technology, we
carried out a study of the spatial distribution of integra-
tion sites in mice with abnormal lymphoproliferations or
healthy controls. Because such a large number of sequence
reads (160 232) were available for analysis, additional
types of analysis became possible, taking advantage of not
just information on the positions of integration sites, but
their frequency of isolation.
A comparison among the tissue distributions of
integration sites in diﬀerent mice revealed a pattern
consistent in one mouse with transformation and accu-
mulation of transformed cells in diverse tissues. Mouse X
had a monoclonal lymphoproliferation based on analysis
of TCR rearrangements. In this mouse, we found that a
relatively small number of integration sites were recovered
from each tissue, but that the most abundant sites were
mostly the same between tissues. Two proto-oncogenes
were located near the most abundant integration sites.
This pattern is as expected for insertional activation of
proto-oncogenes, followed by spread of the transformed
cells to multiple tissues.
One of the goals of this study and others like it is to
identify patterns in integration site data associated with
adverse events, so that similar trends may be monitored in
samples taken early after transplantation from patients
undergoing therapeutic gene transfer. For mouse X, the
high correlation coeﬃcient for integration site identity
and abundance among tissues provides one such read out.
In cases where integration site data are available from
multiple tissues from human gene transfer patients, such a
trend can be assayed for information on possible pro-
gression toward adverse events. Understanding of the
molecular basis of genotoxicity may also allow improved
vector design for future gene therapy trials.
Here, we demonstrate the use of DNA bar coding and
pyrosequencing to analyze the spatial distribution of
transduced clones, but the method also can be applied
to eﬃcient analysis of longitudinal samples. Several
groups have now reported the use of large numbers of
DNA bar codes in single pyrosequencing experiments [this
work and (14–16)]. This allows samples over many time-
points to be analyzed in parallel at reasonable expense.
Another reason for carrying out this study was to
evaluate possible genotoxicity by the lentiviral and
gamma-retroviral vectors used. The numbers of mice
studied here were too small for statistical analysis, but
the integration site data does allow an assessment of
whether insertional activation of proto-oncogenes was
likely to be involved for the individual mice studied.
In both the Artemis and Rag1 correction models, there is
expected to be background transformation rates due
to the mutations and irradiation used during conditioning,
so the ﬁnding of integrated vectors in tumor tissues is
not itself evidence for insertional activation of proto-
oncogenes or inactivation of tumor suppressors. For the
case of Artemis correction using lentiviral vectors,
no increase in the frequency of integration near Cancer-
genes 50 ends was seen in tissues from abnormal
lymphoproliferation, nor was integration near Cancer-
genes more frequent than in control Sca1+cells
(transduced ex vivo) or ﬁbroblasts transduced in cell
culture. This observation does not strengthen the idea
that lentiviral vector integration was involved in causing
transformation—instead, it seems more likely that the
eﬀects of irradiation and the Artemis genetic defect
were responsible. For mouse X, the integrated gamma-
retroviral vectors do seem likely to have contributed to
lymphoproliferation by insertional activation.
We note that there are two possible mechanisms for the
increase in frequency of cells harboring integration near
proto-oncogenes or tumor suppressors during growth
in vivo. First, integration sites near proto-oncogenes may
become more abundant as a fraction of the total during
cell growth, as a result of selective growth advantage
conferred by integration near a gene promoting cellular
proliferation. Second, only a small subset of integration
sites near proto-oncogenes will cause full transformation.
These events probably need to be accompanied by
secondary genomic alterations such as chromosomal rear-
rangements that contribute additional ‘hits’ toward
transformation.
Lastly, we note that the problem of restriction bias in
integration site recovery can be severe. Sampling from the
genomic DNA tested was near saturation for each of the
two enzymes studied in Figures 4 and 5, but only a small
proportion of the integration sites were common to the
two (7.8% of the MseI data set and 28% of the Tsp509I
data set). We have also applied this method to studies of
integration sites in human cells from adverse events
during X-SCID gene therapy, and found examples of
sites involved in adverse events that were diﬃcult or
impossible to isolate after use of certain restriction
enzymes to cleave genomic DNA (39). Most previously
reported methods use restriction enzyme cleavage of
genomic DNA to recover integration sites and so likely
suﬀer from this bias (40). However, using the DNA bar
coding and pyrosequencing protocol described here, it is
possible to examine very large numbers of sequence reads
in a single experiment. Thus it is feasible to use several
diﬀerent restriction enzymes for cleavage and linker
ligation for each sample of interest, thereby maximizing
the diversity of sequences recovered. A combination of
statistical modeling and empirical testing should allow
estimation of the number of diﬀerent enzymes and
pyrosequence reads needed for complete cataloging of
all the integrated vectors present in a genomic DNA
sample.
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Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank members of the Bushman laboratory for
materials and helpful discussions. The MLV GagPol
plasmid is a gift from Paul Bates and Bridget Puﬀer.
Murine embryonic ﬁbroblast is a kind gift from
e49 Nucleic Acids Research, 2008, Vol. 36, No. 9 PAGE 10 OF12Thomas Jenuwein. This work was supported by NIH
grants AI52845, and AI66290 to F.D.B, and by grants
from INSERM, Agence nationale de la recherche (ANR)
05-MRAR-004 and programme hospitalier de recherche
clinique (PHRC) AOM 04052 UA6461. F.B. was sup-
ported by a fellowship from the Association Franc ¸ aise
contre les Myopathies (AFM). A.C. was supported in part
by a fellowship from the Swiss National Science Founda-
tion. G.P.W. was supported by NIH NIAID T32 AI07634
(Training Grant in Infectious Diseases) and University of
Pennsylvania School of Medicine Department of Medicine
Measey Basic Science Fellowship Award. Funding to pay
the Open Access publication charges for this article was
provided by National Institutes of Health.
Conﬂict of interest statement. None declared.
REFERENCES
1. Cavazzana-Calvo,M., Hacein-Bey,S., de Saint Basile,G., Gross,F.,
Yvon,E., Nusbaum,P., Selz,F., Hue,C., Certain,S., Casanova,J.L.
et al. (2000) Gene therapy of human severe combined immunode-
ﬁciency (SCID)-X1 disease. Science, 288, 669–672.
2. Aiuti,A., Slavin,S., Aker,M., Ficara,F., Deola,S., Mortellaro,A.,
Morecki,S., Andolﬁ,G., Tabucchi,A., Carlucci,F. et al. (2002)
Correction of ADA-SCID by stem cell gene therapy combined
with nonmyeloablative conditioning. Science, 296, 2410–2413.
3. Ott,M.G., Schmidt,M., Schwarzwaelder,K., Stein,S., Siler,U.,
Koehl,U., Glimm,H., Kuhlcke,K., Schilz,A., Kunkel,H. et al. (2006)
Correction of X-linked chronic granulomatous disease by gene
therapy, augmented by insertional activation of MDS1-EVI1,
PRDM16 or SETBP1. Nat. Med., 12, 401–409.
4. Hacein-Bey-Abina,S., von Kalle,C., Schmidt,M., Le Deist,F.,
Wulﬀraat,N., McIntyre,E., Radford,I., Villeval,J.L., Fraser,C.C.,
Cavazzana-Calvo,M. et al. (2003) A serious adverse event after
successful gene therapy for X-linked severe combined immunode-
ﬁciency. N. Engl. J. Med., 348, 255–256.
5. Hacein-Bey-Abina,S., von Kalle,C., Schmidt,M., McCormack,M.P.,
Wulﬀraat,N., Leboulch,P., Lim,A., Osborne,C.S., Pawliuk,R.,
Morillon,E. et al. (2003) LMO2-associated clonal T cell
proliferation in two patients after gene therapy for SCID-X1.
Science, 302, 400–401.
6. Schwarz,K., Gauss,G.H., Ludwig,L., Pannicke,U., Li,Z.,
Lindner,D., Friedrich,W., Seger,R.A., Hansen-Hagge,T.E.,
Desiderio,S. et al. (1996) RAG mutations in human B
cell-negative SCID. Science, 274, 97–99.
7. Corneo,B., Moshous,D., Gungor,T., Wulﬀraat,N., Philippet,P.,
Le Deist,F.L., Fischer,A. and de Villartay,J.P. (2001) Identical
mutations in RAG1 or RAG2 genes leading to defective V(D)J
recombinase activity can cause either T-B-severe combined
immune deﬁciency or omenn syndrome. Blood, 97, 2772–2776.
8. Moshous,D., Callebaut,I., de Chasseval,R., Corneo,B.,
Cavazzana-Calvo,M., Le Deist,F., Tezcan,I., Sanal,O., Bertrand,Y.,
Philippe,N. et al. (2001) Artemis, a novel DNA double-strand
break repair/V(D)J recombination protein, is mutated in human
severe combined immune deﬁciency. Cell, 105, 177–186.
9. Mostoslavsky,G., Fabian,A.J., Rooney,S., Alt,F.W. and
Mulligan,R.C. (2006) Complete correction of murine artemis
immunodeﬁciency by lentiviral vector-mediated gene transfer.
Proc. Natl Acad. Sci. USA, 103, 16406–16411.
10. Benjelloun,F., Garrigue,A., Demerens,C., Malassis-Se ´ ris,M.,
Stockholm,D., Blondeau,J., Rivie ` re,J., Lim,A., David,S.P.,
Dutrillaux,R.S. et al. Stable and functional lymphoid
reconstitution in artemis-deﬁcient mice following ex-vivo
gene transfer with lentiviral vector. Mol. Ther., in press
11. Lagresle-Peyrou,C., Yates,F., Malassis-Seris,M., Hue,C.,
Morillon,E., Garrigue,A., Liu,A., Hajdari,P., Stockholm,D.,
Danos,O. et al. (2006) Long-term immune reconstitution in
RAG-1-deﬁcient mice treated by retroviral gene therapy:
a balance between eﬃciency and toxicity. Blood, 107, 63–72.
12. Rooney,S., Sekiguchi,J., Zhu,C., Cheng,H.L., Manis,J., Whitlow,S.,
DeVido,J., Foy,D., Chaudhuri,J., Lombard,D. et al. (2002)
Leaky scid phenotype associated with defective V(D)J
coding end processing in artemis-deﬁcient mice. Mol. Cell, 10,
1379–1390.
13. Margulies,M., Egholm,M., Altman,W.E., Attiya,S., Bader,J.S.,
Bemben,L.A., Berka,J., Braverman,M.S., Chen,Y.J., Chen,Z. et al.
(2005) Genome sequencing in microfabricated high-density
picolitre reactors. Nature, 437, 376–380.
14. Hoﬀmann,C., Minkah,N., Leipzig,J., Wang,G., Arens,M.Q.,
Tebas,P. and Bushman,F.D. (2007) DNA bar coding and
pyrosequencing to identify rare HIV drug resistance mutations.
Nucleic Acids Res., 35, e91.
15. Binladen,J., Gilbert,M.T., Bollback,J.P., Panitz,F., Bendixen,C.,
Nielsen,R. and Willerslev,E. (2007) The use of coded PCR
primers enables high-throughput sequencing of multiple
homolog ampliﬁcation products by 454 parallel sequencing.
PLoS ONE, 2, e197.
16. Shoemaker,D.D., Lashkari,D.A., Morris,D., Mittmann,M. and
Davis,R.W. (1996) Quantitative phenotypic analysis of yeast
deletion mutants using a highly parallel molecular bar-coding
strategy. Nat. Genet., 14, 450–456.
17. Ciuﬃ,A., Llano,M., Poeschla,E., Hoﬀmann,C., Leipzig,J., Shinn,P.,
Ecker,J.R. and Bushman,F.D. (2005) A role for
LEDGF/p75 in targeting HIV DNA integration. Nat. Med., 11,
1287–1289.
18. Wang,G.P., Ciuﬃ,A., Leipzig,J., Berry,C.C. and Bushman,F.D.
(2007) HIV integration site selection: analysis by massively
parallel pyrosequencing reveals association with epigenetic
modiﬁcations. Genome Res., 17, 1186–1194.
19. Mitchell,R., Beitzel,B., Schroder,A., Shinn,P., Chen,H., Berry,C.,
Ecker,J.R. and Bushman,F.D. (2004) Retroviral DNA integration:
ASLV, HIV, and MLV show distinct target site preferences.
PLoS Biol., 2, E234.
20. Wu,X., Li,Y., Crise,B. and Burgess,S.M. (2003) Transcription
start regions in the human genome are favored targets for MLV
integration. Science, 300, 1749–1751.
21. Schmidt,M., Zickler,P., Hoﬀmann,G., Haas,S., Wissler,M.,
Muessig,A., Tisdale,J.F., Kuramoto,K., Andrews,R.G., Wu,T. et al.
(2002) Polyclonal long-term repopulating stem cell clones in a
primate model. Blood, 100, 2737–2743.
22. Huret,J.L., Minor,S.L., Dorkeld,F., Dessen,P. and Bernheim,A.
(2000) Atlas of genetics and cytogenetics in oncology and
haematology, an interactive database. Nucleic Acids Res., 28,
349–351.
23. Akagi,K., Suzuki,T., Stephens,R.M., Jenkins,N.A. and
Copeland,N.G. (2004) RTCGD: retroviral tagged cancer gene
database. Nucleic Acids Res., 32, D523–527.
24. Futreal,P.A., Coin,L., Marshall,M., Down,T., Hubbard,T.,
Wooster,R., Rahman,N. and Stratton,M.R. (2004) A census of
human cancer genes. Nat. Rev. Cancer., 4, 177–183.
25. Sjoblom,T., Jones,S., Wood,L.D., Parsons,D.W., Lin,J.,
Barber,T.D., Mandelker,D., Leary,R.J., Ptak,J., Silliman,N. et al.
(2006) The consensus coding sequences of human breast and
colorectal cancers. Science, 314, 268–274.
26. Berry,C.C., Hannenhalli,S., Leipzig,J. and Bushman,F.D. (2006)
Selection of target sites for mobile DNA integration in the
human genome. 2, e157.
27. Sirven,A., Ravet,E., Charneau,P., Zennou,V., Coulombel,L.,
Guetard,D., Pﬂumio,F. and Dubart-Kupperschmitt,A. (2001)
Enhanced transgene expression in cord blood
CD34(+)-derived hematopoietic cells, including developing
T cells and NOD/SCID mouse repopulating cells, following
transduction with modiﬁed trip lentiviral vectors. Mol. Ther.,
3, 438–448.
28. Holyoake,T.L., Freshney,M.G., Samuel,K., Ansell,J., Watson,G.E.,
Wright,E.G., Graham,G.J. and Pragnell,I.B. (2001) In vivo
expansion of the endogenous B-cell compartment stimulated by
radiation and serial bone marrow transplantation induces B-cell
leukaemia in mice. Br. J. Haematol., 114, 49–56.
29. Schroder,A., Shinn,P., Chen,H., Berry,C., Ecker,J.R. and
Bushman,F.D. (2002) HIV-1 integration in the human genome
favors active genes and local hotspots. Cell, 110, 521–529.
PAGE 11 OF12 Nucleic Acids Research, 2008, Vol. 36, No. 9 e4930. Barr,S.D., Ciuﬃ,A., Leipzig,J., Shinn,P., Ecker,J.R. and
Bushman,F.D. (2006) HIV integration site selection: Targeting
in macrophages and the eﬀects of diﬀerent routes of viral entry.
Mol. Ther., 14, 218–225.
31. Barr,S.D., Leipzig,J., Shinn,P., Ecker,J.R. and Bushman,F.D.
(2005) Integration targeting by avian sarcoma-leukosis virus and
human immunodeﬁciency virus in the chicken genome. J. Virol., 79,
12035–12044.
32. Ciuﬃ,A., Mitchell,R.S., Hoﬀman,C., Leipzig,J., Shinn,P.,
Ecker,J.R. and Bushman,F.D. (2006) Integration site selection by
HIV-based vectors: targeting in dividing and nondividing IMR-90
lung ﬁbroblasts. Mol. Ther., 13, 366–373.
33. Lewinski,M., Bisgrove,D., Shinn,P., Chen,H., Verdin,E.,
Berry,C.C., Ecker,J.R. and Bushman,F.D. (2005) Genome-wide
analysis of chromosomal features repressing HIV transcription.
J. Virol., 79, 6610–6619.
34. Aiuti,A., Cassani,B., Andolﬁ,G., Mirolo,M., Biasco,L., Recchia,A.,
Urbinati,F., Valacca,C., Scaramuzza,S., Aker,M. et al. (2007)
Multilineage hematopoietic reconstitution without clonal selection
in ADA-SCID patients treated with stem cell gene therapy. J. Clin.
Invest., 117, 2233–2240.
35. Lewinski,M., Yamashita,M., Emerman,M., Ciuﬃ,A., Marshall,H.,
Crawford,G., Collins,F., Shinn,P., Leipzig,J., Hannenhalli,S. et al.
(2006) Retroviral DNA integration: viral and cellular
determinants of target site selection. PLOS Pathogens, 2, e60.
36. De Palma,M., Montini,E., Santoni de Sio,F.R., Benedicenti,F.,
Gentile,A., Medico,E. and Naldini,L. (2005) Promoter trapping
reveals signiﬁcant diﬀerences in integration site selection between
MLV and HIV vectors in primary hematopoetic cells. Blood, 105,
2307–2315.
37. Turlure,F., Maertens,G., Rahman,S., Cherepanov,P. and
Engelman,A. (2006) A tripartite DNA-binding element,
comprised of the nuclear localization signal and two AT-hook
motifs, mediates the association of LEDGF/p75 with chromatin
in vivo. Nucleic Acids Res., 34, 1653–1675.
38. Cattoglio,C., Facchini,G., Sartori,D., Antonelli,A., Miccio,A.,
Cassani,B., Schmidt,M., von Kalle,C., Howe,S., Thrasher,A.J. et al.
(2007) Hot spots of retroviral integration in human CD34+
hematopoietic cells. Blood, 110, 1770–1778.
39. Hacein-Bey-Abina,S., Garrigue,A., Wang,G.P., Soulier,J., Lim,A.,
Morillon,E., Clappier,E., Caccavelli,L., Delabesse,E., Beldjord,K.,
et al. (2008) Oncogenesis by insertional activation in four patients
afters retrovirus-mediated gene therapy of SCID-X1, submitted for
publication.
40. Schmidt,M., Hoﬀmann,G., Wissler,M., Lemke,N., Mubig,A.,
Glimm,H., Williams,D.A., Ragg,S., Hesemann,C.-. and von
Kalle,C. (2001) Detection and direct genomic sequencing of
multiple rare unknown ﬂanking DNA in highly complex samples.
Hum. Gene Ther., 12, 743–749.
e49 Nucleic Acids Research, 2008, Vol. 36, No. 9 PAGE 12 OF12